Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven A.J. Salamon, and Aharon Gil filed Amendment No. 9 to a Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership in PolyPid Ltd. as of September 30, 2026.

Key Highlights

  • Four reporting persons: Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven A.J. Salamon, and Aharon Gil each report aggregate beneficial ownership of 4,735,367 shares.
  • Ownership percentage: Each reporting person is listed at 9.6% of the class, calculated based on 21,125,704 ordinary shares outstanding as of September 30, 2026.
  • Composition of reported shares: The 4,735,367 figure includes 177,011 shares of common stock held directly and 4,558,356 shares issuable upon exercise of warrants.
  • Blocker provision applies: According to the filing, the warrants contain a blocker provision preventing exercise if it would result in beneficial ownership exceeding 9.99% of common stock; as a result, the reporting persons state they "were not able to exercise any of the warrants due to the Blockers" as of the event date.
  • Actual direct holdings lower: The filing states that Rosalind Master Fund L.P. may be deemed to beneficially own 177,011 shares of common stock, representing approximately 0.84% of outstanding shares, excluding the warrant shares blocked from exercise.
  • No sole voting or dispositive power: All four reporting persons report sole voting power of 0 and sole dispositive power of 0; shared voting and dispositive power over 4,735,367 shares each.
  • Disclaimer of beneficial ownership: According to the filing, Rosalind Advisors, Inc. and Steven Salamon "disclaim beneficial ownership of the shares."

Rosalind Group's PolyPid Position: Warrants, Blockers, and Shared Control

The Schedule 13G Amendment No. 9 covers PolyPid Ltd. (CUSIP M8001Q126), an Israeli biopharmaceutical company headquartered at 18 Hasivim Street, Petach Tikva, Israel. The filing was triggered by an event dated September 30, 2026, and was submitted on November 13, 2026. The outstanding share count of 21,125,704 is cited as drawn from a Form 6-K issued by PolyPid Ltd. on November 11, 2026.

The four reporting persons - Rosalind Advisors, Inc. (incorporated in Ontario, Canada), Rosalind Master Fund L.P. (organized in the Cayman Islands), Steven A.J. Salamon, and Aharon Gil (both Canadian citizens resident in Ontario) - share voting and dispositive power over 4,735,367 shares. Rosalind Advisors, Inc. serves as investment adviser to Rosalind Master Fund L.P. Steven Salamon is identified as portfolio manager of the Adviser, and Aharon Gil is identified as portfolio manager and member of the Adviser. The filing notes that the 9.6% figure reported for each person does not give effect to the blocker provisions attached to the warrants, and that the actual shares beneficially owned after accounting for those blockers is less than the number shown in rows 6, 8, and 9 of the cover pages.

The filing states that the 4,558,356 warrant shares are excluded from the directly exercisable position because a blocker provision prevents any exercise that would push the holder's beneficial ownership above 9.99%. As a result, the directly held common stock position of 177,011 shares, representing approximately 0.84% of outstanding shares, reflects the operative ownership level subject to the blocker constraint. The certifications section states the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Rosalind Advisors, Inc. and three affiliated reporting persons filed Amendment No. 9 to Schedule 13G, disclosing aggregate reported beneficial ownership of 4,735,367 PolyPid Ltd. common shares (9.6%), comprising 177,011 direct shares and 4,558,356 warrant shares subject to a 9.99% blocker provision that prevents current exercise.